Immudicon Overview
- Phone Number
- Available in AeroLeads
- Website
- immudicon.com
- Industry
- Biotechnology Research
- Employees
- 6
- Founded
- 2011
- Company Email
- Available in AeroLeads
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
About Immudicon
Immudicon is developing MacroVax, an intracellular vaccine delivery technology, to activate the immune system against cancer and potentially other disease indications. Initial research & trials of our technology have been shown in vitro in both mouse and human cell types, as well as in vivo to explicate T-cell specificity to tumor antigens, cytokine activation profiles, and early-stage prophylactic trials.